Polidocanol Sclerotherapy for the Treatment of Pyogenic Granuloma in Children

Dermatol Surg. 2021 Jun 1;47(6):802-804. doi: 10.1097/DSS.0000000000002967.

Abstract

Background: Pyogenic granuloma (PG) is a benign vascular lesion that is commonly observed in the skin and mucosa. Sclerotherapy is the first-line conservative treatment option for PG.

Objective: This retrospective study aimed to evaluate the efficacy of sclerotherapy with 1.0% polidocanol for the treatment of PG.

Materials and methods: All patients who were clinically diagnosed with PG consecutively at the Pediatric Outpatient Service of Qilu Children's Hospital of Shandong University from March 2018 to October 2019 received sclerotherapy with 1.0% polidocanol.

Result: The procedure resulted in the complete excision of PG, with inconspicuous scars. The procedure was well-tolerated, and recurrence was not observed. Allergic reactions, cutaneous necrosis, and pigmentary changes were not observed.

Conclusion: Sclerotherapy with 1.0% polidocanol is considered an effective treatment for PGs in children. Early treatment was associated with a more favorable outcome.

MeSH terms

  • Child
  • Child, Preschool
  • Cicatrix / chemically induced
  • Cicatrix / diagnosis
  • Female
  • Granuloma, Pyogenic / therapy*
  • Humans
  • Infant
  • Injections, Intralesional / adverse effects
  • Male
  • Polidocanol / administration & dosage*
  • Polidocanol / adverse effects
  • Recurrence
  • Retrospective Studies
  • Sclerosing Solutions / administration & dosage*
  • Sclerosing Solutions / adverse effects
  • Sclerotherapy / adverse effects
  • Sclerotherapy / methods*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Sclerosing Solutions
  • Polidocanol